Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women (Q48853983)

16 February 2018

title

Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women (English)

1 reference

16 February 2018

author name string

Y E Chung

1

1 reference

16 February 2018

S H Lee

2

1 reference

16 February 2018

S-Y Lee

3

1 reference

16 February 2018

S-Y Kim

4

1 reference

16 February 2018

H-H Kim

5

1 reference

16 February 2018

F S Mirza

6

1 reference

16 February 2018

S-K Lee

7

1 reference

16 February 2018

J A Lorenzo

8

1 reference

16 February 2018

G S Kim

9

1 reference

16 February 2018

J-M Koh

10

1 reference

16 February 2018

language of work or name

English

0 references

publication date

10 June 2011

1 reference

16 February 2018

Osteoporosis International

published in

1 reference

16 February 2018

volume

23

1 reference

16 February 2018

issue

4

1 reference

16 February 2018

page(s)

1235-1243

1 reference

16 February 2018

Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Regulation of circulating sclerostin levels by sex steroids in women and in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Sclerostin: a gem from the genome leads to bone-building antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Glucocorticoid-induced bone fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Primary hyperparathyroidism and the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Bone remodeling during fracture repair: The cellular picture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Molecular determinants for the tissue specificity of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Control of the SOST bone enhancer by PTH using MEF2 transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1675-1

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

21 January 2018

1 reference

12 December 2020

Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study

1 reference

12 December 2020

Osteoporosis in rheumatoid arthritis and ankylosing spondylitis

1 reference

12 December 2020

Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption

1 reference

12 December 2020

Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk

1 reference

12 December 2020

Sex steroids and the construction and conservation of the adult skeleton

1 reference

12 December 2020

10.1007/S00198-011-1675-1

Identifiers

DOI

1 reference

16 February 2018

1 reference

16 February 2018